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Biofi lm delays wound healing: A review of the 
evidence
Biofilm natural history and medical 
significance
Bacteria are ubiquitous in nature, and while the majority 
are harmless and important in life and for human health, 
some are capable of  causing disease. Whether they develop 
within natural or pathogenic ecosystems, bacteria have a 
preference for existence as a surface-attached community, 
rather than as a planktonic (free-floating) mode of  life. It 
has been suggested that bacteria evolved as surface-attached 
organisms, and that a planktonic phenotype subsequently 
evolved as a dispersal and seeding mechanism.[1]
The observation of  bacterial aggregation and attachment 
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to the surface of  teeth was first made by van Leewenhoek 
in the late 1600s, but it was not until the 1970s, when 
researchers had access to more advanced microscopy 
and traditional microbiology techniques, that the true 
significance of  surface-attached bacteria in ecosystems 
as diverse as the bovine stomach and alpine streams was 
realized. Investigation of  granite rocks in a Canadian alpine 
stream revealed that the bacterial population embedded 
within a slippery slime layer on rock surfaces outnumbered 
planktonic bacteria in the steam water by a factor of  1,000-
10,000;[2,3] this emphasizes the preference of  bacteria to 
attach to surfaces. It was during this period that the term 
‘biofilm’ was first used to describe surface-adherent bacteria 
encased within, and protected by a self-produced glycocalyx 
(today more commonly referred to as extracellular 
polymeric substance, or EPS).[3] Biofilm research since 
the 1970s has been extensive, with substantial evidence 
indicating that bacteria exist predominantly as a biofilm 
phenotype in medical, natural and industrial ecosystems.[3] 
The impact of  biofilm in waste water filtration, biofouling 
of  industrial materials, metal corrosion, and human chronic 
bacterial infections has been widely documented.
A B S T R A C T
Biofi lm is the predominant mode of life for bacteria and today it is implicated in numerous human diseases. A growing body of 
scientifi c and clinical evidence now exists regarding the presence of biofi lm in wounds. This review summarizes the clinical 
experiences and in vivo evidence that implicate biofi lm in delayed wound healing. The various mechanisms by which biofi lm may 
impede healing are highlighted, including impaired epithelialization and granulation tissue formation, and reduced susceptibilities to 
antimicrobial agents and host defenses. Strategies to manage biofi lm and encourage progression to wound healing are discussed; 
these include debridement and appropriate antimicrobial therapies which may be improved upon in the future with the emergence 
of anti-biofi lm technologies.
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Today, biofilm is implicated in numerous bacterial infections 
including those associated with the urinary tract, ear, sinuses, 
indwelling catheters, cystic fibrosis, periodontal disease and 
chronic wounds. Research undertaken during the 1970s, 
predominantly pioneered by J. William Costerton (the father 
of  biofilmology), showed that ‘healthy’ biofilm on normal 
tissue surfaces provided protection against pathogenic 
colonization,[4] and that pathogenic biofilm predominated 
in infected tissues associated with chronic endocarditis and 
indwelling devices.[5] Additionally, it became evident that 
infections associated with bacterial biofilm persisted despite 
aggressive antimicrobial chemotherapy.[6] Biofilm tolerance 
to antimicrobial agents[7] and host defense mechanisms[8,9] is 
now well documented, and this highlights the importance 
of  effective biofilm management in chronic infections.
There is no doubt that biofilm exists in some wounds, and 
in the last decade a growing body of  supportive evidence 
has emerged.[10-13] Table 1 summarizes some key scientific 
evidence for the presence of  biofilm in wounds.[10,11,14-19] It 
is likely that at least half  of  all chronic wounds contain 
biofilm,[10,11] the implications of  which are considerable. If  a 
majority of  non-healing wounds contain biofilm, and it has 
a role in delayed healing, then biofilm could be contributing 
many billions of  dollars to the global cost of  chronic 
wounds.[20,21] Recent evidence from animal models has 
demonstrated that biofilm creates a low-grade and persistent 
inflammatory response, and impairs both epithelialization 
and granulation tissue formation.[22] Additionally, due to 
clinical observations of  suspected biofilm, specific biofilm-
based wound management is now being practised.[12] This 
review will focus on the most recent clinical experiences and 
in vivo evidence from relevant animal models to summarize 
the latest knowledge of  the effects of  biofilm on wound 
healing.
Biofilm and wound healing
Clinical evidence 
In a series of case studies, Hurlow (2009 and 2012) described 
management of  wound biofilm using carefully selected 
combinations of debridement, antimicrobials and dressing 
technologies [Table 2].[13,23] Figure 1 shows an example of an 
infected traumatic wound undergoing curettage to debride 
biofilm that appeared to be impeding granulation tissue 
formation. Careful management of infection, exudate and 
underlying pathophysiologies were complemented by this 
approach.[23] Hurlow’s work also highlighted key differences 
between the origins, composition and behavior of slough and 
biofilm. Slough is dead or devitalized proteinaceous host tissue, 
but contiguous with underlying viable tissue.[13] On the other 
hand, biofilm is viable, bacteria-derived tissue, comprised of  
bacteria in a matrix of EPS which is thought to be primarily 
polysaccharide-based.[28] This distinction is exemplified 
in Figure 2 which shows a dehisced surgical wound with 
suggestive biofilm in addition to peripheral slough. The claim 
that biofilm is sometimes visible in wounds with the naked 
eye[23] has initiated lively debate amongst the global wound 
care community.[29] A shiny, translucent, slimy layer in the 
wound bed had already been used as a clinical sign of biofilm, 
especially if  it returned quickly after sharp debridement.[30] It 
has recently been argued that there is no conclusive in vivo 
proof that biofilm exists in wounds per se; however, the authors 
highlight the need for biofilm detection technology and support 
biofilm-based wound care (BBWC).[31]
In recent years, Wolcott and colleagues have embarked on 
a series of  clinical investigations which have advanced our 
understanding of  the characterization, behavior and impact 
of  biofilm in chronic and acute wounds [Table 2].[12,24-27]
Table 1: Key scientific evidence for the presence of biofilm in human wounds
Wound type No. Methods Observations Reference
Chronic wounds 50 Light microscopy, scanning electron 
microscopy (SEM)
30 (60%) chronic wounds observed to 
contain biofilm
James et al.  (2008) [10]
Acute wounds 16 Light microscopy, SEM 1 (6%) acute wound contained biofilm James et al.  (2008) [10]
Chronic wounds 22 Confocal microscopy 13 (59%) chronic wounds contained 
biofilm
Kirketerp-Møller et al. (2008) [11]
Chronic wounds 2 Fluorescence microscopy Both samples contained biofilm Bjarnsholt et al. (2008) [14]
Chronic wounds 10 Fluorescence microscopy, confocal 
microscopy
Pseudomonas aeruginosa biofilm 
seen deeper in wound bed than 
Staphylococcus aureus
Fazli et al. (2009)[15]
Chronic wounds 10 Fluorescence microscopy, confocal 
microscopy
P. aeruginosa biofilm elicited  greater 
inflammation than S. aureus
Fazli et al. (2011)[16]
Mixed etiologies 15 Fluorescence microscopy 7 (47%) wounds contained biofilm Han et al. (2011)[17]
Diabetic foot ulcers 2 Confocal microscopy Both samples contained biofilm Neut et al. (2011)[18]
Full-thickness burns 11 Light microscopy,  transmission electron 
microscopy, SEM
Ulcerated areas and escharotomy sites 
contained biofilm; non-ulcerated areas 
did not 
Kennedy et al. (2010)[19]
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BBWC is an algorithm, including debridement, antimicrobial 
dressings, anti-biofilm agents and antibiotics, used to most 
efficiently suppress wound biofilm and encourage healing. 
In a retrospective clinical study, the improved level of  
healing achieved using BBWC was found to be statistically 
significant.[12] The value of  regular debridement was 
demonstrated in a series of  scientific, animal and clinical 
analyses, which showed that debridement opens up a 
therapeutic window where bacteria are more susceptible to 
antimicrobial agents,[32] so is key to maintaining a healthy 
wound bed.[33] A recent retrospective study examined a 
group of  97 patients with various wounds that received 
BBWC in conjunction with cell-based therapy. Compared 
to previous studies which did not use BBWC, these bespoke 
protocols of  care were shown to result in a statistically 
significant improvement in wound healing following 
cell-based therapy.[27] Figure 3 shows an example of  how 
debridement in conjunction with a silver carboxymethyl 
cellulose dressing was used to successfully transform a 
biofilm-colonized dehisced incision [Figure 3a] to a healing 
wound [Figure 3b].
These clinical experiences, case studies and retrospective 
studies are of  great value as we begin to understand the 
effect of  biofilm on wound healing. However, in the absence 
of  a non-invasive, point-of-care biofilm detection method, it 
is challenging to use human patients to conduct randomized 
or prospective trials on the subject. It is also unethical to 
consider deliberate establishment of  biofilm in human 
patients. Therefore, the use of  animal models is justifiable 
in investigating this significant human health problem. 
Moreover, certain animal wound models are relevant to 
human wound healing in terms of  host response such as 
the production of  macrophages, neutrophils, inflammatory 
enzymes and keratinocytes. Porcine, murine and rabbit ear 
wound models are all recognized for their value in better 
understanding human wound pathophysiology and healing.
Animal evidence 
Studies using the porcine acute wound model suggested 
that biofilm physically impairs the immune responses 
associated with healing [Table 3].[34,35] The authors described 
how continuous antimicrobial treatment was needed to 
control biofilm-colonized wounds, and that debridement 
was a critical step to reduce bioburden before therapeutics 
are applied,[49] as has been described clinically.[32,33] A 
porcine model has demonstrated that encouraging the 
establishment and resilience of  wound biofilm exacerbates 
delayed healing [Table 3].[36] Most recently, the interaction 
between S. aureus and P. aeruginosa in biofilms has been 
demonstrated in the porcine model where healing was 
significantly delayed [Table 3].[37] Murine models have been 
used to demonstrate the importance of  P. aeruginosa biofilm-
forming virulence factors,[38] and that EPS protects bacteria 
from antibiotics and host defenses [Table 3].[39] The diabetic 
Table 2: Clinical evidence that biofilm delays wound healing
Wound type No. Clinical observations Biofilm management Reference
Non-healing surgical ulcer 1 Cloudy, shiny, thin film of slime, after lavage, 
enzymatic ointment and a silver alginate dressing
Curettage gently scraped away film; 
managed underlying pathophysiology
Hurlow & Bowler (2009)[13]
Venous leg  ulcer (VLU) 1 Thick, visible film, after lavage, collagenase 
debridement and a silver alginate dressing
Continual debridement plus negative 
pressure wound therapy and split-
thickness graft
Hurlow & Bowler (2009)[13]
VLU 1 Persistent, cloudy,  translucent film, after a silver 
alginate dressing
Sodium hypochlorite wound cleanser 
between dressing changes
Hurlow & Bowler (2009)[13]
Diabetic with cellulitis 2 Visible, opaque, pale yellow films Antibiotics, debridement and a silver 
carboxymethyl cellulose dressing
Hurlow & Bowler (2012)[23]
Highly exuding 3 Thick, green-tinted or  translucent film, after 
inappropriate dressings (polyurethane, hydrogel 
or foam dressings)
Two wounds healed using 
antibiotics, debridement and a silver 
carboxymethyl cellulose dressing
Hurlow & Bowler (2012)[23]
Peripheral arterial disease (PAD) 3 Cloudy and translucent film / opaque film / red/
green film
Sharp debridement and a silver  
carboxylmethyl cellulose  dressing
Hurlow & Bowler (2012)[23]
Critically  ischemic lower limb 
wounds
190 77% (146) wounds healed Combinations of sharp and ultrasonic 
debridement, lactoferrin/xylitol, 
cadexomer iodine and silver dressings
Wolcott & Rhoads (2008)[12]
Dehisced 4 Healing Sharp debridement Wolcott et al. (2010)[24]
Lower limb traumatic in a PAD 
patient
1 Wound had become chronic with suspected 
biofilm
Healed over 6 months using BBWC Wolcott et al. (2010)[25] 
Traumatic chemical burn in a 
diabetic
1 Infection developed and  patient was declared an 
amputation case
Healed in 12 weeks using  
debridement, systemic and topical 
antibiotics and silver dressings
Wolcott & Dowd (2011)[26]
Mixed etiologies undergoing 
cell-based therapy
97 Entire graft material remained intact with biofilm 
suppression
Debridement and personalised topical 
gels containing anti-biofilm agents and 
antibiotics
Wolcott & Cox (2013)[27]
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mouse chronic wound model has shown that P. aeruginosa 
biofilm significantly delayed healing by two to four 
weeks without impairing the general health of  the subject 
[Table 3].[40,41] Treating diabetic mice with insulin did not 
prevent delayed healing, actually promoting P. aeruginosa 
biofilm [Table 3],[42] which has also been shown to be 
resistant to undiluted sodium hypochlorite.[32] Polymicrobial 
biofilm comprised of  four species delayed murine wound 
closure significantly more than single-species biofilm over 
12 days [Table 3].[43]
The Northwestern University group in Chicago has 
conducted a series of  in vivo studies in recent years, 
expanding our understanding of  the effect of  biofilm on 
wound healing [Table 3]. Visible biofilm was observed to 
significantly delay closure of  the epithelial gap in a murine 
splinted wound model [Table 3],[44] before an established, 
reproducible and Food & Drug Administration (FDA)-
recognized rabbit dermal ulcer model of  wound healing was 
adopted.[50] This model utilizes full-thickness punch wounds 
through to the cartilage of  rabbit ears, closely representing 
the dermal damage observed in human chronic wounds. 
Biofilms of  S. aureus[22] and P. aeruginosa[45] significantly 
delayed healing in terms of epithelialization and granulation 
tissue formation, with biofilm-colonized wounds expressing 
significantly lower levels of  inflammatory markers than 
clinically infected wounds [Table 3]. Combinations of  
treatments in an anti-biofilm protocol of  care were also 
shown to be more effective at encouraging wound healing 
than individual treatments [Table 3].[45] Biofilms of  the 
opportunistic pathogen, Klebsiella pneumoniae, associated 
with burn and war wounds, were shown to impair healing 
of  ischemic rabbit ear wounds,[46] but to a lesser extent 
than P. aeruginosa or S. aureus [Table 3].[47] A further study 
demonstrated synergy between different species in biofilm, 
further delaying wound healing compared to single-species 
biofilm [Table 3],[48] as has been demonstrated in murine 
models.[43]
Despite the limitations of  the rabbit ear wound healing 
model (e.g. an acute wound modeling a human chronic 
wound), its advantages over other animal models are clear 
and have recently been the subject of  a review.[51] As a 
highly controlled in vivo wound biofilm model, the rabbit 
ear model is also useful for assessing new anti-biofilm or 
antimicrobial technologies.[52,53]
Figure 2: A dehisced surgical incision in a relatively ischemic patient. 
The opaque fi lm on the wound bed (centre) re-formed daily and could 
be lifted off to reveal intact granular buds. Ultrasonic debridement was 
ineffective at disrupting or removing this thick, mature biofi lm. Slough 
is also evident on the intact skin around the wound (top centre, top 
right, bottom right).
Figure 1: An infected traumatic leg ulcer in a diabetic patient with 
moderate peripheral arterial disease. Curettage was used to remove 
the pale yellow, slimy biofi lm from the wound. Small buds of granulation 
tissue can be seen beneath the biofi lm.
Figure 3: A dehisced mastectomy incision wound in a patient who 
had undergone chemotherapy. (a) Debridement in conjunction with 
a silver carboxymethyl cellulose dressing was used to transform a 
biofi lm colonized wound. (b) Debridement in conjunction with a silver 
carboxymethyl cellulose dressing was used to transform a healing 
wound.
a b
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Management of wound biofilm 
Based on the clinical and in vivo experiences summarized 
above, it is possible to devise effective anti-biofilm strategies, 
similar to BBWC, to encourage wound healing in every-
day clinical practice. Indeed, the Tissue-Inflammation/
Infection-Moisture-Edge (TIME) concept has recently 
been updated to include biofilm management as a key 
consideration in wound bed preparation.[54]
Debridement
Physical debridement of  foreign material is clearly the 
simplest, and currently the most effective method to 
remove these impediments to healing. Whilst clinicians 
have long appreciated that debridement of  slough can 
encourage healing, the evidence suggests that this process 
also removes bacteria, in the form of  contaminated 
or colonized slough, as well as biofilm. Debridement 
techniques range from specialist surgical and sharp 
debridement, gentler mechanical debridement with curettes, 
fabric pads, lavage or ultrasound, to autolytic debridement 
with moisture-retentive dressings.[55] There may also be a 
place for chemical debridement using rinse solutions or 
gels containing antiseptics such as sodium hypochlorite or 
hypochlorous acid.[56,57] Whichever method is utilized, the 
main clinical and in vivo observations are that biofilm re-forms 
Table 3: Animal evidence that biofilm delays wound healing from porcine, murine and rabbit ear wound models
Model Biofilm species Observations Reference
Porcine acute  wound S. aureus Challenge with antimicrobial agents confirmed the  recalcitrance of 
biofilm bacteria
Serralta et al. (2001)[34]
Porcine acute wound S. aureus Indirect evidence of delayed healing, with  polymorphonucleocytes 
observed on the surface of, but not within, biofilm
Davis et al.  (2008)[35]
Porcine acute wound Methicillin-resistant 
S. aureus (MRSA)
Greater healing delays were observed due to biofilm formed by 
passaged MRSA strains than by parent strains; passaged strain was 
observed to form more biofilm than parent strain
Roche et al. (2012)[36]
Porcine partial-thickness wound MRSA, P. aeruginosa Interactions between MRSA and P. aeruginosa were  observed, 
delaying healing due to suppression of epithelialization and 
expression of virulence factors
Pastar et al. (2013)[37]
Murine burn P. aeruginosa A biofilm-forming factor established in vitro was a key virulence 
factor in vivo
Rashid et al. (2000)[38]
Murine burn P. aeruginosa Microscopic biofilm that was not readily removed by rinsing 
with saline
Schaber et al. (2007)[39]
Murine diabetic chronic wound P. aeruginosa (In vitro then inoculated) biofilm significantly delayed healing 
compared to controls; health parameters in biofilm-colonized mice 
were normal
Zhao et al. (2010)[40]
Murine diabetic chronic wound P. aeruginosa (In vitro then inoculated) biofilm-colonized wounds had high levels 
of inflammatory cells; 8 weeks for all biofilm-colonized wounds to 
heal, compared to 4 weeks for controls
Zhao et al. (2012)[41]
Murine diabetic chronic wound P. aeruginosa Biofilm significantly delayed wound healing, even in diabetic mice 
treated with insulin
Watters et al. (2012)[42]
Murine chronically infected surgical 
wound
P. aeruginosa Biofilm was highly resistant to antibiotics and undiluted sodium 
hypochlorite once established over several days
Wolcott et al. (2010)[32]
Murine chronically infected surgical 
wound
S. aureus, P. aeruginosa, 
Enterococcus faecalis,  
Finegoldia magna
(In vitro then inoculated) polymicrobial biofilm was  maintained for 
12 days, and delayed healing more than P. aeruginosa biofilm, as 
measured by wound closure
Dalton et al. (2011)[43]
Murine splinted wound S. aureus or Staphylococcus 
epidermidis
Biofilms significantly delayed epithelialization; inhibition of biofilm 
restored normal wound healing
Schierle et al. (2009)[44]
Rabbit ear wound S. aureus Biofilm and active infection significantly delayed epithelialization 
and granulation tissue formation; biofilm-colonized wounds 
expressed significantly lower levels of inflammatory cytokines than 
infected wounds
Gurjala et  al. (2011)[22]
Rabbit ear wound P. aeruginosa Biofilm significantly delayed epithelialization and  granulation 
tissue formation; debridement, lavage and silver sulphadiazine in 
combination were more effective at restoring healing than individual 
treatments
Seth et al. (2012a)[45]
Rabbit ischemic ear wound Klebsiella pneumoniae Biofilm formed readily in ischemic wounds but not in  non-ischemic 
wounds where neutrophils and macrophages were seen
Seth et al. (2012b)[46]
Rabbit ischemic ear wound K. pneumoniae, S. aureus, 
P. aeruginosa
K. pneumoniae biofilm was least virulent, P. aeruginosa biofilm most 
virulent, measured by healing inhibition and inflammatory 
responses; EPS-deficient P.  aeruginosa did not delay healing
Seth et al. (2012c)[47]
Rabbit ear wound S. aureus, P. aeruginosa Two-species biofilm elicited significantly elevated inflammatory 
response and impaired epithelialization and granulation tissue 
formation compared to single-species biofilm
Seth et al. (2012d)[48]
Burns & Trauma • June 2013 • Vol 1 • Issue 1 10
Metcalf and Bowler: Biofilm delays wound healing
rapidly-certainly daily, and likely within hours,[58] so regular 
debridement is key.[32,33] In addition, whereas slough may 
be contiguous with healthier underlying host tissue, biofilm 
may be more surface-associated so may respond well to 
gentler methods of  debridement such as curettage, fabric 
pads or skin-safe chemical rinses. Moreover, although the 
aim of  debridement is to remove devitalized tissue and 
‘beat back’ biofilm to stop it re-forming,[32,33] it will only be 
effective if  followed up with appropriate antimicrobials and 
wound management products.
Topical antimicrobials
The abundance of  currently-available antimicrobial 
agents (e.g. antibiotics, cleansers, gels, dressings) may be 
confusing to healthcare professionals. Antibiotics should 
be used responsibly and only when clinical infection is 
suspected or confirmed by clinical and microbiological 
assessment. Effective debridement of  biofilm removes some 
of  the protection bacteria are offered by EPS, forcing the 
remaining bacteria to revert to a more metabolically active 
form, so antibiotics (which are designed to kill planktonic 
bacteria), and topical antiseptics such as silver, iodine 
and polyhexamethylene biguanide (PHMB), are made 
more effective.[32,33] Perhaps as important as the antiseptic 
selected is the delivery vehicle used, which must interact 
optimally with the wound microenvironment. For example, 
in an exuding wound with suspected biofilm, a highly-
absorbent antiseptic dressing should be used after effective 
debridement-the use of  antiseptic gauze or mesh would 
be inappropriate, due to their poor exudate management 
capabilities. Prudent combinations of  debridement, 
antimicrobials and wound management products is 
currently the best available protocol of  care for wounds with 
suspected biofilm or infection.[12] However, the anti-biofilm 
efficacy of  most currently available topical antimicrobial 
products is limited.
Anti-biofilm agents
As we begin to appreciate the source (bacterial), composition 
(EPS or ‘slime’) and behavior (re-forms quickly) of  wound 
biofilm, opportunities to improve on current wound 
care are presented. For example, in the future it may 
be possible to formulate wound care products, such as 
debridement pads, rinses or dressings, with agents that 
penetrate through biofilm EPS, thus exposing the bacteria 
and increasing their susceptibility to antimicrobials. 
Detergent-type agents could help to remove biofilm from 
the wound bed, or chemicals could be used that weaken the 
matrix to collapse biofilms which could then be mopped 
up by absorbent dressings. A number of  such potential 
anti-biofilm agents have been proposed, such as xylitol, 
lactoferrin and ethylenediaminetetraacetic acid (EDTA),[12] 
but convincing clinical or in vivo evidence for their efficacy 
is lacking. A key challenge to science and industry is to 
better understand the composition of  wound biofilm in 
terms of  polysaccharide, protein, extracellular DNA and 
ions, in order to formulate anti-biofilm technologies. At least 
daily, we all use combinations of  debridement, detergents 
and antimicrobials to manage oral plaque biofilm and 
maintain oral hygeine,[59] and this multi-modal approach is 
most likely how wound biofilm can be effectively managed 
to encourage wound healing.
Biofilm detection
The current accepted gold standard for biofilm detection 
in wounds is by microscopic examination using expensive 
and specialized techniques such as confocal microscopy or 
electronic microscopy. Although in some instances, biofilm 
may be visible to the trained clinical eye,[13,23,30] the need for 
wound biofilm detection techniques for use at the point-of-
care is clear.[31,54,60] Biofilm detection would enable more 
effective wound bed preparation techniques if  the clinician 
could visualize if  and where biofilm is present in the wound, 
perhaps by staining or tagging biofilm components to render 
them visible.[60] This would also enable the most appropriate 
and effective selection of  antimicrobials and dressings, with 
associated cost savings, which are becoming increasingly 
important in global healthcare.
Conclusion
By taking into account the growing body of  scientific and 
clinical evidence regarding wound biofilm, this review 
has highlighted a multitude of  mechanisms by which 
biofilm may be implicated in delayed healing. Biofilm is 
associated with impaired epithelialization and granulation 
tissue formation, and promotes a low-grade inflammatory 
response that interferes with wound healing. Polymicrobial 
biofilms, which invariably exist in chronic wounds, have 
been shown to delay healing to a greater extent than single-
species biofilms. Taking these effects into account, wound 
biofilm likely evolves as a cryptic ecosystem that at some 
point is sufficiently established to interfere with wound 
healing, and if  not managed effectively may progress to 
infection. 
From a therapeutic perspective, multi-modal approaches 
to wound management, particularly involving frequent 
physical debridement and antimicrobial therapy have 
been shown to enhance healing to a greater extent than 
single therapies in both animal and human studies. Whilst 
frequent physical removal of  wound biofilm and appropriate 
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antibiotic and topical antimicrobial therapies are perhaps 
best practice today, there is clearly a need for new medical 
devices (including dressings) that are able to interfere with 
the complex biofilm communities that exist in non-healing 
wounds.
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